کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2802638 | 1156699 | 2015 | 7 صفحه PDF | دانلود رایگان |
• GH is reduced in states of visceral obesity and may contribute to increased CV risk.
• GHRH provides a strategy to increase endogenous pulsatile growth hormone secretion.
• GHRH reduces visceral fat and ameliorates dyslipidemia in HIV-infected individuals.
• Data suggest that GHRH may have metabolic and cardiovascular benefit in obesity.
Increased visceral adipose tissue (VAT) is associated with reductions in endogenous GH secretion, possibly as a result of hyperinsulinemia, increased circulating free fatty acid, increased somatostatin tone, and reduced ghrelin. Reduced GH may, in turn, further exacerbate visceral fat accumulation because of decreased hormone-sensitive lipolysis in this depot. Data from multiple populations demonstrate that both reduced GH and increased VAT appear to contribute independently to dyslipidemia, increased systemic inflammation, and increased cardiovascular risk. The reductions in GH in states of visceral adiposity are characterized by reduced basal and pulsatile GH secretion with intact pulse frequency. Treatment with GH-releasing hormone (GHRH) provides a means to reverse these abnormalities, increasing endogenous basal and pulsatile GH secretion without altering pulse frequency. This review describes data from HIV-infected individuals and individuals with general obesity showing that treatment with GHRH significantly reduces visceral fat, ameliorates dyslipidemia, and reduces markers of cardiovascular risk. Further research is needed regarding the long-term efficacy and safety of this treatment modality.
Journal: Growth Hormone & IGF Research - Volume 25, Issue 2, April 2015, Pages 59–65